(Q37164836)

18 August 2017

1 reference

title

Age considerations when vaccinating against HPV. (English)

1 reference

18 August 2017

3

Bradley J Monk

1 reference

18 August 2017

Thomas C Wright

1

1 reference

18 August 2017

Warner K Huh

2

1 reference

18 August 2017

Jennifer S Smith

4

1 reference

18 August 2017

Kevin Ault

5

1 reference

18 August 2017

Thomas J Herzog

6

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

109

1 reference

18 August 2017

issue

2 Suppl

1 reference

18 August 2017

page(s)

S40-7

1 reference

Chapter 14: HPV vaccine introduction in industrialized countries

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

HPV vaccination--more answers, more questions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

Prevalence of HPV infection among females in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

Seroprevalence of human papillomavirus type 16 infection in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

A population-based study of cervical carcinoma and HPV infection in Latvia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.002

10.1016/J.YGYNO.2008.02.002

7 January 2021

Identifiers

DOI

1 reference

18 August 2017

1 reference